D espite recent advances in the treatment of multiple myeloma, patients with this disease still inevitably relapse and become refractory to existing therapies. Mutations in K-RAS, N-RAS and B-RAF are common in multiple myeloma, affecting 50% of patients at diagnosis and >70% at relapse. However, targeting mutated RAS/RAF via MEK inhibition is merely cytostatic in myeloma and largely ineffective in the clinic. We examined mechanisms mediating this resistance and identified histone deacetylase inhibitors as potent synergistic partners. Combining the MEK inhibitor AZD6244 (selumetinib) with the pan-histone deacetylase inhibitor LBH589 (panobinostat) induced synergistic apoptosis in RAS/RAF mutated multiple myeloma cell lines. Interestingly, this synergy was dependent on the pro-apoptotic protein BIM. We determined that while single-agent MEK inhibition increased BIM levels, the protein remained sequestered by anti-apoptotic BCL-2 family members. LBH589 dissociated BIM from MCL-1 and BCL-X L , which allowed it to bind BAX/BAK and thereby initiate apoptosis. The AZD6244/LBH589 combination was specifically active in cell lines with more BIM:MCL-1 complexes at baseline; resistant cell lines had more BIM:BCL-2 complexes. Those resistant cell lines were synergistically killed by combining the BH3 mimetic ABT-199 (venetoclax) with LBH589. Using more specific histone deacetylase inhibitors, i.e. MS275 (entinostat) and FK228 (romidepsin), and genetic methods, we determined that concomitant inhibition of histone deacetylases 1 and 2 was sufficient to synergize with either MEK or BCL-2 inhibition. Furthermore, these drug combinations effectively killed plasma cells from myeloma patients ex vivo. Given the preponderance of RAS/RAF mutations, and the fact that ABT-199 has demonstrated clinical efficacy in relapsed/refractory multiple myeloma, these drug combinations hold promise as biomarker-driven therapies.
Histone deacetylase inhibition in combination with MEK or BCL-2 inhibition in multiple myeloma
suggesting a role in disease progression. 7, 10 Furthermore, >70% of patients have RAS/RAF mutations present at relapse. 11 It follows that directly targeting RAS/RAF/MEK/ERK in MM could be a promising strategy. However, MEK inhibition is merely cytostatic in MM in vitro. 12 Furthermore, a clinical trial evaluating MEK inhibitor monotherapy in MM showed limited efficacy. 13 Thus, it appears that for MEK inhibitors to be relevant in MM, they must be combined with other agents.
Recently, histone deacetylase (HDAC) inhibitors have shown significant activity in numerous tumor types, both in vitro and in the clinic. 14 In fact, the pan-HDAC inhibitor LBH589 (panobinostat) was recently approved for treating relapsed/refractory MM patients in combination with bortezomib. 15 As chemotherapeutic agents, HDAC inhibitors have been shown to inhibit cell survival and proliferation and enhance immune-mediated cytotoxicity. 14, 15 We hypothesized that LBH589 could induce enhanced apoptosis when combined with MEK inhibition in MM. Our hypothesis stemmed from two considerations: (i) MEK inhibitors induce apoptosis in several other RAS/RAF mutated cancers, 16, 17 suggesting MM-specific resistance factors, and (ii) HDAC inhibitors kill MM cells through several known mechanisms, including modulation of the pro-and anti-apoptotic BCL-2 family members, which often mediate chemoresistance. 15, [18] [19] [20] In the present study, we show that MEK inhibition with AZD6244 (selumetinib), when combined with LBH589, synergistically drives intrinsic apoptotic cell death in MCL-1 "primed" RAS/RAF mutated MM cell lines. Mechanistically, MEK inhibition increases BIM levels; LBH589 acts as a de facto MCL-1 and BCL-X L inhibitor, dissociating BIM:MCL-1 and BIM:BCL-X L complexes. In contrast, we demonstrate that LBH589 synergizes with the BH3 mimetic ABT-199 (venetoclax) in BCL-2 "primed" cell lines, which are resistant to the AZD6244/LBH589 combination. Finally, we show that concomitant inhibition of HDAC1 and HDAC2 is sufficient to synergize with either MEK or BCL-2 inhibition in the same distinct MM cell lines.
Given that refractoriness to whole classes of drugs (e.g. proteasome inhibitors) is the final common endpoint for nearly all patients with MM, 21 the agents in this study are felicitous because they work via alternative mechanisms of action, are already approved or in clinical development, and offer the tantalizing prospect of targeted therapy guided by RAS/RAF mutational status and MCL-1/BCL-2 functional dependence.
Methods

Ethics
This study was approved by the Mayo Clinic Institutional Review Board. Patients' cells were collected after informed consent, in adherence to the Declaration of Helsinki.
Multiple myeloma cell lines and patients' cells
DOX40, H929, KMS11, KMS18, KMS28BM, MM1S, MM1R, OPM1, OPM2, RPMI8226 and U266 were obtained (see Online Supplementary Methods). 19, 22 Briefly, all cell lines were cultured in RPMI 1640 medium (Mediatech Inc., Manassas, VA, USA) containing 10% fetal bovine serum (Mediatech, Inc.). Freshly obtained bone marrow aspirates from MM patients were collected after informed consent, then CD138 + or bone marrow stromal cells were sorted and cultured as previously described. 19, 22 Reagents was generously provided by Abbvie (Chicago, IL,  USA). AZD6244, MEK162, SCH772984, SAHA, LBH589, MS275  and FK228 were purchased from Selleckchem (Houston, TX,  USA) . Tubacin was purchased from Sigma-Aldrich (St. Louis, MO, USA). Stock solutions were made in dimethylsulfoxide, aliquoted and stored at −20°C.
MTT, proliferation, and apoptosis assays
Cellular viability was measured using 3-(4, 5-dimethylthiazol-2yl)-2, 5-diphenyl tetrasodium bromide (MTT) (Chemicon International Inc., Temecula, CA, USA) colorimetric assays at the indicated time points. Proliferation arrest assays were completed using 3 H-thymidine uptake as previously described. 23 Apoptosis of patients' cells was assayed using annexin/propidium iodide (PI) as previously described. 22, 23 Briefly, cells were washed twice with annexin binding buffer (ABB: 10 mM HEPES pH 7.4, 140 mM NaCl, 2.5 mM CaCl 2 ) and then 100 μL cells (10 7 /mL) were stained for 15 min at room temperature with 3 μL of annexin V-FITC (Caltag, Burlingame, CA, USA), then washed with ABB and resuspended in 500 μL of ABB with 5 μL of 1 mg/mL PI (Sigma-Aldrich, St. Louis, MO, USA). The samples were then run on a Canto flow cytometer (BD Biosciences, San Jose, CA). All experiments with MM cell lines were performed in triplicate.
Western blotting
MM cell lines were lysed with NP40 buffer, 1 mM phenylmethyl-sulfonyl-fluoride (PMSF), protease inhibitor cocktail (PIC), and 1 mM HALT Phosphatase Inhibitor (Thermo Fisher Scientific, Rockford, IL, USA). Protein concentrations were measured using the BCA assay (Thermo Fisher). First, 20-25 μg were loaded on 4-20% Tris-Glycine gels and transferred onto polyvinylidene difluoride membranes (Bio-Rad, Hercules, CA , USA). Antibodies for acetylated histone 3, BAK, BAX, BCL-2, BCL-X L , BIM, caspase 8, caspase 9, ERK, GAPDH, HDAC1, HDAC2, HDAC6, MCL-1, PARP, p-BCL-2 (S70), pERK, p-MCL-1 (S64), and p-MCL-1 (T163) were purchased from Cell Signaling Technology (Danvers, MA, USA) and used for probing as previously described. 19, 22 All western blot experiments were performed in triplicate with a representative blot shown.
Immunoprecipitation
Proteins (100-150 μg) were incubated in a total volume of 500 μL of NP40 buffer, 1 mM PMSF, 1 mM PIC, 1 mM HALT Phosphatase Inhibitor (Thermo Fisher Scientific), and a 1:100 dilution of the following primary antibodies for 4 h: BAX 6A7 (Santa Cruz Biotechnology, Santa Cruz, CA, USA), BAX (Millipore Sigma, Burlington, MA, USA), and BCL-2, BCL-X L , BIM and MCL-1 (Cell Signaling Technology). Samples were then incubated with ChIP-Grade Protein G Magnetic Beads (Cell Signaling Technology) for 12 h, washed five times, boiled in 2x Laemmli Sample Buffer dye (Bio-Rad) at 100 ºC for 5 min, then loaded on 4-20% Tris-Glycine gels (Bio-Rad) and probed as described above. All experiments were performed in triplicate with a representative blot shown.
Short interfering RNA transfection
Short interfering (si)RNA for BIM, BAX, BAK, HDAC1, HDAC2 and HDAC6 were purchased from Thermo Fisher Scientific. ERK1 and ERK2 siRNA were purchased from Santa Cruz Biotechnology. siRNA were electroporated into MM cell lines using the Lonza nucleofector kit V (Lonza, Basel, Switzerland). The manufacturer's G-15 program was used for KMS18 and OPM2; O-23 was used for MM1S and KMS28. All experiments were performed in triplicate.
Isobologram analysis
The effects of combination treatments in MM cells were analyzed using the CalcuSyn™ software program (Biosoft, Ferguson, MO, USA), which is based on the Chou-Talalay method, as previously described. 19, 24 
Results
Single-agent MEK inhibition does not induce cell death in multiple myeloma cell lines
Prior studies have documented the lack of induction of cytotoxicity by single-agent MEK inhibitors in MM. 12 We aimed to confirm these findings using a panel of MM cell lines that are wild-type or mutated for RAS/RAF. We treated cell lines with increasing doses of the MEK inhibitor AZD6244 (selumetinib) and observed a lack of significant cytotoxicity, with IC 50 not reached at doses up to 1500 nM (Online Supplementary Figure 1A ). AZD6244 was slightly more capable at inducing proliferation arrest in the same panel of cell lines, but still largely ineffective (Online Supplementary Figure 1B) . These results were also confirmed by performing annexin/PI staining after treating two RAS mutant MM cell lines with 5000 nM of AZD6244, which is far above the concentrations at which the kinase activity of MEK is inhibited (Online Supplementary Figure 1C ). Thus, it became clear that despite commonly occurring oncogenic mutations in RAS and RAF, MEK inhibitors have limited scope as singleagents in MM.
MEK + HDAC inhibition induces synergistic cell death in multiple myeloma cell lines
We examined the ability of the recently approved pan-HDAC inhibitor LBH589 (panobinostat) to enhance cell death induced by AZD6244 in MM cell lines. Low doses of the AZD6244/LBH589 drug combination induced potent synergistic cytotoxicity ( Figure 1A) . Interestingly, the synergy was observed in cell lines with mutations in K-RAS and N-RAS (i.e. H929, MM1R, MM1S, RPMI8226) and B-RAF (i.e. U266), but not in cell lines that are wildtype for RAS and RAF (i.e. KMS11, KMS18, OPM2). We also observed significantly more potent proliferation arrest when the drugs were used in combination ( Figure  1B) .
Components of the bone marrow microenvironment such as bone marrow stromal cells play an indispensable role in MM disease progression and resistance to therapies. 25 We therefore investigated whether AZD6244/LBH589 was able to overcome the protective effects of bone marrow stromal cells. To do this, we cocultured MM1S cells with patient-derived bone marrow stromal cells and measured the proliferation rate after treatment with either single-agent AZD6244 or LBH589, or the drug combination. We observed that the AZD6244/LBH589 combination was able to inhibit the proliferation of MM1S even when co-cultured with bone marrow stromal cells ( Figure 1C ). We also noted synergistic cell death when we used another MEK inhibitor, MEK162 (binimetinib), or the ERK inhibitor SCH772984 in combination with LBH589 (Online Supplementary Figure  1D ). Furthermore, AZD6244 synergistically killed MM cells when combined with the pan-HDAC inhibitor SAHA (data not shown).
To understand whether the cytotoxicity caused by the AZD6244/LBH589 combination occurred through the apoptotic pathway, we performed annexin/PI staining. The drug combination clearly induced apoptotic cell death by 72 h (Figure 2A ). We also examined whether the combination induced the cleavage of caspases and PARP, both of which are markers of apoptosis. The AZD6244/LBH589 combination induced potent cleavage of caspase 9 and PARP, but not caspase 8, suggesting that the cell death occurred through the mitochondrial intrinsic apoptotic pathway ( Figure 2B ). Next, we examined whether the drugs, at the doses used above, were able to inhibit their target proteins. As expected, AZD6244 inhibited pERK and LBH589 caused an increase in acetylated histone H3 levels ( Figure 2C ). Finally, to confirm that MEK/ERK pathway inhibition contributed to the synergy with LBH589, and to examine whether both isoforms of ERK need to be inhibited for the synergy to occur, we nucleofected isoform-specific ERK siRNA into MM1S and treated the cells with LBH589. We observed that ERK1 or ERK2 knockdown individually enhanced the cell death induced by LBH589 ( Figure 2D , E). However, simultaneous knockdown of both isoforms led to even more pronounced cell death when used in combination with LBH589, supporting an important survival role for both ERK isoforms in this context. Finally, we treated plasma cells obtained from MM patients with the drug combination. The characteristics of these patients are detailed in Online Supplementary Table S1 . It is worth noting that several patients had high-risk features including TP53 deletion, t(4;14) and refractoriness to multiple lines of therapy. We observed augmented apoptosis with the AZD6244/LBH589 drug combination compared to the effects of either drug alone (Table 1) .
MEK + HDAC inhibitor-induced synergistic apoptosis is mediated by BIM
Given that the MEK/ERK pathway is known to phosphorylate the pro-apoptotic BH3-only protein BIM at serine 69 (S69) to mark it for proteasomal degradation, 26 we were not surprised to find that AZD6244 treatment increased BIM protein levels ( Figure 3A ). Although prior studies have shown that HDAC inhibition increases BIM expression in MM, 18, 19 we did not observe increased levels of BIM with the several-fold lower doses of LBH589 that were used in this study ( Figure 3A ). Even so, given that MEK inhibition increased BIM and that the drug combination induced potent activation of intrinsic apoptotic markers, we hypothesized that BIM might play an important role in the observed synergy. To investigate this, we nucleo fected MM1S cells with BIM siRNA and observed that BIM knockdown completely protected from the synergistic cell death induced by the MEK + HDAC inhibitor combination ( Figure 3B ).
HDAC inhibition dissociates BIM from MCL-1 and BCL-X L
From the above results, it became clear that BIM plays an essential role in the synergistic apoptosis induced by the drug combination. Since BIM was upregulated by AZD6244, but not by LBH589, we reasoned that the increased levels of BIM induced by AZD6244 were unable to activate apoptosis due to sequestration by the antiapoptotic BCL-2 family members (i.e. BCL-2, BCL-X L and MCL-1). Thus, we hypothesized that the mechanism by which LBH589 synergizes with AZD6244 is by modulating the interactions of BIM with the anti-apoptotic BCL-2 A B C family proteins. In pursuit of demonstration of this, we immunoprecipitated BIM and examined its binding pattern with BCL-2, BCL-X L and MCL-1 before and after drug treatment. AZD6244 increased the relative amount of BIM bound to all three anti-apoptotic proteins, which may partly explain why even though the drug markedly increases BIM levels, it has limited cytotoxic effects in MM as a single agent ( Figure 3C ). Interestingly, LBH589 dissociated BIM from MCL-1 and BCL-X L , but not BCL-2 ( Figure 3C ). This effect was particularly evident when the anti-apoptotic proteins were "primed" with more BIM by AZD6244. We also noted this dissociation in the reciprocal experiment when pulling down with BCL-2 and MCL-1, and probing for BIM ( Figure 3C ). Furthermore, we observed increased BIM bound to both BAX and BAK after AZD6244 and LBH589 treatment individually, which was markedly increased after the combination treatment ( Figure 3D ). We also noted that LBH589 dissociated BAK from MCL-1 in a similar manner to BIM, which theoretically would facilitate increased BIM:BAK complexes in the presence of LBH589 to further activate the intrinsic apoptotic cascade ( Figure 3D ).
MCL-1/BCL-2 expression and BIM binding profile correlate with sensitivity to MEK + HDAC inhibition
In light of LBH589 dissociating BIM from MCL-1 and BCL-X L , but not from BCL-2, we wondered if the cell lines that were resistant to the MEK+HDAC inhibitor combination expressed higher baseline levels of BCL-2. Western blots confirmed that this was partly true, but many of the AZD6244/LBH589-sensitive cell lines, including MM1R, MM1S, RPMI8226 and U266, had high expression of both BCL-2 and MCL-1 ( Figure 4A ). To interrogate the possibility that expression is a poor indication of functional dependence on either anti-apoptotic protein, we immunoprecipitated BIM and examined baseline levels of BIM:BCL-2, BIM:MCL-1 and BIM:BCL-X L complexes in cell lines that were either sensitive or resistant to the MEK + HDAC inhibitor combination. Notably, BIM was mostly bound to MCL-1 in all of the cell lines which were sensi-HDAC + MEK or BCL-2 inhibition in multiple myeloma haematologica | 2019; 104(10) 2065 
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C tive to the MEK + HDAC inhibitor combination, including the aforementioned MM1R, MM1S, RPMI8226 and U266, suggesting that MCL-1 that is "BIM-primed" is critical for the observed synergy to occur ( Figure 4A ). On the other hand, cell lines with BIM mostly bound to BCL-2 were resistant to the MEK + HDAC inhibitor combination ( Figure 4A ). It was noteworthy that BCL-X L was weakly expressed in most of the cell lines and there were few BIM:BCL-X L complexes at baseline ( Figure 4A ).
BCL-2 + HDAC inhibition induces synergistic apoptosis in MEK + HDAC inhibitor-resistant, BCL-2-primed cell lines
Since cell lines with more BIM:BCL-2 complexes relative to BIM:MCL-1 complexes were resistant to the MEK + HDAC combination, we hypothesized that these BCL-2-primed cell lines would be sensitive to BCL-2 inhibition with the BH3 mimetic ABT-199 (venetoclax) when used in combination with LBH589. Remarkably, BCL-2 + HDAC inhibition caused synergistic proliferation arrest and cytotoxicity in nearly all the cell lines that were resistant to the MEK + HDAC combination, including DOX40, KMS18, KMS28 and OPM2 ( Figure 4B and data not shown). Pronounced induction of apoptosis was confirmed by annexin/PI staining (Online Supplementary Figure S2 ).
This coincided with cleavage of caspase 9/3 and PARP ( Figure 4C) . Immunoprecipitation experiments demonstrated that ABT-199 dissociated BIM from BCL-2, and LBH589 dissociated BIM from MCL-1 ( Figure 4D ). In addition, we found that ABT-199 and LBH589 both increased BIM bound to both BAX and BAK, an effect that was even more pronounced with the drug combination ( Figure 4E ). Moreover, BAX/BAK knockdown with siRNA protected from the ABT-199/LBH589-induced cytotoxicity, confirming that the observed synergistic cell death occurred via the mitochondrial intrinsic apoptotic pathway ( Figure 4F ). Table 1 . Changes in apoptosis of multiple myeloma patients' plasma cells exposed to various drug combinations. Plasma cells sorted from patients with multiple myeloma were exposed to AZD6244, LBH589, and the combination, or ABT-199, LBH589, and the combination for 72 h. The proportion of cells undergoing apoptosis was measured using flow cytometry, and the relative fold change in apoptosis is indicated. The upper part of the table summarizes the results from the 14 patients treated with the AZD6244/LBH489 combination, while the lower part summarizes the results for the nine patients treated with the ABT-199/LBH589 combination. Finally, we noted enhanced apoptosis after treating plasma cells from MM patients with the ABT-199/LBH589 combination (Table 1) . Notably, the ABT-199/LBH589 combination did not synergistically induce cell death in the RAS/RAF mutant, AZD6244/LBH589-sensitive cell lines (i.e. H929, MM1R, MM1S, RPMI and U266). This dovetails with the finding that while LBH589 dissociated BIM:MCL-1 complexes in all the cell lines we tested, it did not shift BIM onto BCL-2 in RAS/RAF mutant cell lines (e.g. MM1S) ( Figure 3C ). However, LBH589 did shift BIM onto BCL-2 in the RAS/RAF wild-type cell lines (e.g. OPM2) ( Figure 4D ), which jibes with its potent synergistic effect when combined with ABT-199. In summary, it appears that AZD6244/LBH589 and ABT-199/LBH589 target two distinct subgroups of MM cell lines with different BCL-2 family binding proclivities.
Drug dose (nM) Relative fold change in apoptosis
Baseline MCL-1/BCL-2 phosphorylation status correlates with sensitivity to MEK + HDAC or BCL-2 + HDAC inhibition
To determine why certain cell lines would preferentially have BIM bound to one anti-apoptotic protein over another, i.e. BCL-2 versus MCL-1, we examined several phosphorylation sites known to affect the binding capacity and stability of the BCL-2 family to see if there was any correlation. Interestingly, cell lines with higher p-BCL-2 at serine 70 (S70) tended to have more BIM bound to BCL-2 ( Figure 5A ). p-BCL-2 (S70) is known to increase the antiapoptotic capacity of BCL-2, i.e. its ability to bind BAK and BH3-only proteins. 27 On the other hand, cell lines with BIM mostly bound to MCL-1 tended to have relatively low expression of p-BCL-2 (S70), as well as relatively high expression of p-MCL-1 at threonine 163 (T163) ( Figure 5A ). p-MCL-1 HDAC + MEK or BCL-2 inhibition in multiple myeloma haematologica | 2019; 104(10) 2067 (T163) is a well-documented post-translational modification that stabilizes MCL-1, protecting it from proteasomal degradation. 28 However, we did not observe a correlation between p-MCL-1 at serine 64 (S64) and BIM binding preference (data not shown). p-MCL-1 (S64) increases the binding capacity of MCL-1, but not its stability. 29 To our surprise, p-BCL-2 (S70) and p-MCL-1 (T163) were nearly perfect in predicting sensitivity to either MEK + HDAC or BCL-2 + HDAC inhibition ( Figure 5A ). This was particularly striking in the case of DOX40, a doxorubicin-resistant cell line derived from RPMI8226. DOX40 expressed more p-BCL-2 (S70) than p-MCL-1 (T163), and was sensitive to the ABT-199/LBH589 combination, whereas its parental cell line RPMI8226 did not express p-BCL-2 (S70), but did express p-MCL-1 (T163), and was sensitive to the AZD6244/LBH589 combination ( Figure  5A ). Interestingly, the only cell line we tested that was resistant to both drug combinations was KMS11, and this line has low expression of both p-BCL-2 (S70) and p-MCL-1 (T163) ( Figure 5A ).
RAS/RAF mutational status predicts sensitivity to MEK + HDAC or BCL-2 + HDAC inhibition
Since MEK inhibitors target the pathway downstream of RAS/RAF, we were curious to determine whether sensitivity to the AZD6244/LBH589 combination correlates with RAS/RAF mutational status. This is a felicitous prospect because the MEK/ERK pathway in part controls p-MCL-1 (T163). 28 Indeed, the RAS-mutated cell lines H929, MM1R, MM1S, RPMI8226, and the RAF-mutated (Figures 1A and 5A ). On the other hand, the RAS/RAF wild-type cell lines KMS18 and OPM2 were resistant to MEK + HDAC inhibition, but sensitive to BCL-2 + HDAC inhibition. These cell lines also had high expression of p-BCL-2 (S70) ( Figures 4B and 5A ). However, the correlation between sensitivity to either drug combination and RAS/RAF mutational status was not perfect: DOX40 and KMS28 both have mutated RAS, but were sensitive to BCL-2 + HDAC inhibition rather than to MEK + HDAC inhibition. Finally, KMS11, which was resistant to both combinations, has wild-type RAS/RAF. Thus, we conclude that p-BCL-2 (S70), p-MCL-1 (T163) and RAS/RAF mutational status could all be useful biomarkers to predict for sensitivity to either the MEK + HDAC or BCL-2 + HDAC inhibitor combinations.
HDAC inhibition alters the phosphorylation of MCL-1
Given that HDAC inhibition dissociated BIM from MCL-1, we investigated whether LBH589 altered the expression of any BH3-only proteins that could theoretically bind to MCL-1 to displace BIM. However, at the doses at which we observed synergy, LBH589 did not appreciably alter the expression of any of the BH3-only proteins, including NOXA, PUMA, BAD, BID, BIK, BMF or HRK (data not shown). Since we found that baseline post-translational modifications on several of the antiapoptotic BCL-2 family members correlated with sensitivity to either drug combination, we studied whether LBH589 altered any post-translational modifications on MCL-1 or BCL-X L that could explain the BIM dissociation.
Interestingly, LBH589 down regulated p-MCL-1 (S64) in a time-and dose-dependent manner ( Figure 5B ). In addition, AZD6244 increased p-MCL-1 (S64), which may explain in part why MCL-1 becomes "primed" with BIM after AZD6244 treatment ( Figure 5C ). When the drugs were combined, LBH589 still decreased p-MCL-1 (S64) when compared to AZD6244 alone ( Figure 5C ). Taken together, it seems that LBH589 might facilitate apoptosis by decreasing the phosphorylation of MCL-1 at the S64 residue, making it less "sticky" to BIM, especially after it becomes primed with BIM in the context of MEK inhibitor treatment. 29 p-MCL-1 (S64) is known to be driven by JNK, 29 and CDK1/2. 29, 30 However, we were unable to replicate synergy when we used JNK or CDK inhibitors in combination with AZD6244 or ABT-199 (data not shown). Relatively less is known about the role of post-translational modifications on BCL-X L , but similar to BCL-2 and MCL-1, phosphorylation has been documented to modulate the antiapoptotic role of BCL-X L . 20 However, LBH589 did not appreciably alter p-BCL-X L (S62) levels (data not shown).
HDAC6 inhibition does not enhance apoptosis induced by MEK inhibition
Next, we wanted to identify which HDAC(s) must be inhibited for the observed synergy to occur with MEK or BCL-2 inhibitors. First, we examined the role of HDAC6 given the relevance of inhibiting the aggresome pathway in MM and early clinical results obtained using HDAC6 inhibition in the relapsed/refractory setting. 15, 31 Treating cells with AZD6244 in combination with the HDAC6specific inhibitor tubacin did not lead to synergistic cell HDAC + MEK or BCL-2 inhibition in multiple myeloma haematologica | 2019; 104(10) 2069 Figure S3A) . These results were confirmed by knocking down HDAC6 using siRNA (Online Supplementary Figure S3B) . Considering all the findings, we concluded that HDAC6 inhibition does not seem to be important for the synergistic cell death induced by the AZD6244/LBH589 combination.
Simultaneous inhibition of HDAC1 and HDAC2 is sufficient to enhance cell death induced by MEK or BCL-2 inhibition
We next examined whether inhibiting class I HDAC augmented cell death in combination with MEK or BCL-2 inhibitors. For this, we first used MS275 (entinostat), which inhibits HDAC1, 2 and 3. We observed potent synergy when MS275 was used with AZD6244 or ABT-199 in MM cell lines (Online Supplementary Figure S4A, B) and patients' cells (Online Supplementary Table S2 ) similar to the synergy observed with LBH589. This synergy occurred even at very low doses of MS275 (i.e. 150 nM), which would be unlikely to inhibit HDAC3 (the IC 50 for HDAC3 is 1.7 μM). 32 To determine whether inhibiting HDAC1 and 2 would be sufficient to synergize with AZD6244 or ABT-199, we used the HDAC1 and 2 inhibitor FK228 (romidepsin) in combination with V.G. Ramakrishnan et al. 2070 haematologica | 2019; 104(10) (Figure 6A , B) and patients' cells (Online Supplementary Table S2 ). Using western blotting and immunoprecipitation, we also replicated the mechanistic finding that FK228 downregulates p-MCL-1 (S64) and causes BIM dissociation from MCL-1 and BCL-X L in KMS28 ( Figure 6C ) and H929 (Online Supplementary Figure  S4C ). This strongly suggested that HDAC1 and 2 are involved in the mechanism. To confirm these results, we performed knockdown studies with HDAC1-and HDAC2-specific siRNA. Knocking down HDAC1 and HDAC2 individually in combination with AZD6244 or ABT-199 caused minor increases in apoptosis. However, simultaneous knockdown of both HDAC1 and HDAC2, when combined with AZD6244 or ABT-199, caused significantly more apoptosis (Figure 6D , E). Inhibiting HDAC3 in addition to HDAC1 and HDAC2 did not augment the synergy (data not shown). Dovetailing with our results with pharmacological HDAC inhibitors, we observed p-MCL-1 (S64) downregulation when HDAC1 and HDAC2 were silenced in tandem ( Figure 6D ). We also noted that knocking down either HDAC1 or HDAC2 individually caused a reciprocal upregulation of HDAC2 and HDAC1, respectively. We speculate that this could be the reason why inhibition of HDAC1 or HDAC2 individually was not sufficient to synergize with either MEK or BCL-2 inhibition ( Figure 6D, E) . Taken together, these results showed that simultaneous inhibition of HDAC1 and HDAC2 is sufficient to markedly enhance the apoptosis induced by AZD6244 or ABT-199 in MM.
Discussion
The sequestration of pro-apoptotic BCL-2 family proteins, such as BIM, by their anti-apoptotic counterparts, i.e. BCL-2 and MCL-1, is a pervasive survival strategy in cancer. 20 Hence, treatments that alter the pro/anti-apoptotic BCL-2 family member ratio or modulate their binding dynamics hold considerable promise, particularly in hematologic malignancies. In the present study, we identified two drug combinations, i.e. MEK + HDAC and BCL-2 + HDAC inhibition, which target two distinct subgroups of MM: MCL-1 or BCL-2 primed, respectively (summarized in Figure 7 ). In support of these being discrete phenotypes, none of the MM cell lines that we tested was sensitive to both drug combinations. Furthermore, sensitivity aligned mostly based on RAS/RAF mutational status.
Mutations in the RAS/RAF pathway are present in nearly half of all malignant tumor types. 33 In lieu of a direct way to inhibit RAS, MEK inhibitors have shown significant clinical benefit in several RAS/RAF-mutated cancers. 34 Herein, we identified that RAS/RAF-mutated MM HDAC + MEK or BCL-2 inhibition in multiple myeloma haematologica | 2019; 104(10) 2071 Figure 7 . Proposed mechanism of MEK or BCL-2 inhibition in combination with histone deacetylase inhibition in multiple myeloma. (A) MCL-1-primed lines, which all had mutated RAS/RAF, were sensitive to the MEK + histone deacetylase (HDAC) inhibitor combination. MEK inhibition increased BIM levels, and HDAC1+2 inhibition dissociated BIM:MCL-1 and BIM:BCL-X L complexes, the former perhaps by means of downregulation of p-MCL-1 (S64). (B) BCL-2-primed cell lines tended to be wild-type (WT) for RAS/RAF, and were sensitive to the BCL-2+HDAC inhibitor combination. Likewise, HDAC1+2 inhibition dissociated BIM:MCL-1 complexes. Both drug combinations in effect increased free BIM levels, which we found were able to engage BAX and BAK, ultimately leading to synergistic apoptotic cell death.
other HDAC1/2-containing complexes could achieve greater efficacy with potentially less toxicity. 50 
